Abstract
Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Current Respiratory Medicine Reviews
Title: New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III
Volume: 3 Issue: 2
Author(s): Marcus B. Conde and Margarita Elsa Villarino
Affiliation:
Keywords: Tuberculosis, drugs, treatment, diarylquinolines, fluoroquinolones, clinical trial
Abstract: Tuberculosis (TB) remains a serious global health problem. The infrastructure necessary for delivering the TB treatment regimens recommended for use today accounts for more than two-thirds of the total cost of treating TB patients. Reducing the duration of the treatment regimen from the currently recommended six months to two months could result in significant cost savings and make treatment available to more patients worldwide. The objective of this review is to highlight potential new agents for treatment of drug-susceptible TB disease that are currently under study or were recently evaluated through clinical trials. We conducted a literature search in the English language for clinical studies as well as an electronic computer-assisted and manual search. The literature search was conducted on August 30, 2006, using MEDLINE (2000-2006), EMBASE (2000-2006) and the National Institute of Health (NIH) Clinical Trials Register database (2000-2006). Most of the new agents identified as anti-TB drug candidates are still in the preclinical phases. Only the diarylquinolines and the fluoroquinolones are being evaluated for potential inclusion in new ultra-short TB treatment regimens through clinical studies phases II/III. In this article, we present a summary of the studies reviewed and discuss their potential for modifying future treatment recommendations for TB treatment.
Export Options
About this article
Cite this article as:
Conde B. Marcus and Elsa Villarino Margarita, New Agents for the Treatment of Tuberculosis on Clinical Study Phases II/III, Current Respiratory Medicine Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339807780599144
DOI https://dx.doi.org/10.2174/157339807780599144 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Genetic Interactions in Lung Diseases Detection Using Computational
Approaches: A Review
Current Chinese Computer Science Absorption, Disposition and Pharmacokinetics of Solid Lipid Nanoparticles
Current Drug Metabolism Antiviral Activity and Molecular Targets of Plant Natural Products Against Avian Influenza Virus
Current Organic Chemistry <i>In Vivo</i> Anti-Candida Activity of <i>Artemisia herba alba</i> asso and <i>Citrus aurantium</i> Extracts Formulated in Different Ointments
Anti-Infective Agents Recent Developments in Antitubercular Drugs
Mini-Reviews in Medicinal Chemistry Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Synthesis and In Vitro Evaluation of Novel 1, 2, 4-Triazole Derivatives as Antifungal Agents
Letters in Drug Design & Discovery Interplay between Catalysts and Substrates for Activity of Class Ib Aminoacyl-tRNA Synthetases and Implications for Pharmacology
Current Topics in Medicinal Chemistry Synthesis, Biological Profile, and Molecular Docking of Some New Bis- Imidazole Fused Templates and Investigation of their Cytotoxic Potential as Anti-tubercular and/or Anticancer Prototypes
Medicinal Chemistry Identification of Antimycobacterial Agent Using In Silico Virtual Screening, ADME Prediction, Docking, and Molecular Dynamics Simulations Approach
Current Computer-Aided Drug Design The Intermediate Enzymes of Isoprenoid Metabolism as Anticancer Targets
Anti-Cancer Agents in Medicinal Chemistry Assessment of the Physicochemical Properties and Stability for Pharmacokinetic Prediction of Pyrazinoic Acid Derivatives
Current Drug Metabolism Discrimination of Chemical Profiles of Some Bacterial Species by Analyzing Culture Headspace Air Samples Using TD-GC/MS
Current Analytical Chemistry Using Genomics for Natural Product Structure Elucidation
Current Topics in Medicinal Chemistry Identifying the Structural Features of Diphenyl Ether Analogues for InhA Inhibition: A 2D and 3D QSAR Based Study
Letters in Drug Design & Discovery 1,2,3-Triazole-Isoxazole Based Acetylcholinesterase Inhibitors: Synthesis, Biological Evaluation and Docking Study
Letters in Drug Design & Discovery Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Synthesis, Characterizations and Microbial Studies of Novel Mannich Products Using Multicomponent Reactions
Current Bioactive Compounds